Effect of i.c.v. infusion of the alpha-MSH agonist MTII on meal patterns in male rats following nicotine withdrawal.

Bellinger L, Cepeda-Benito A, Bullard RL, Wellman PJ

Life sciences1 Aug 2003Cited by 17 (Europe PMC)

PMID12888124DOI10.1016/s0024-3205(03)00485-5PepBankPUB-12888124

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

4 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In rats, third ventricle MTII 30 ng suppressed dark phase food intake in both saline-treated and nicotine-withdrawn groups.
In plain wordsIn rats, melanotan II infused into the brain reduced night-time food intake, in both saline-treated rats and rats withdrawn from nicotine.
Peptide
Melanotan II
Outcome
DecreaseDark phase food intake after MTII
Study
ratn: not reported in source
Male Sprague Dawley rats with third ventricle cannulas, nicotine withdrawal
Comparator
Artificial cerebrospinal fluid (aCSF)
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
30 ng/rat · third ventricle infusionAs given in this study (rat).
Source sentences
Summary
Infusion of MTII (30 ng/rat) suppressed (P < 0.01) dark phase food intake in both groups
1 context sentence(design, population, supporting numbers)
Summary · context
On day 22, the rats were divided into 4 groups (n's = 7-8 each) and injected into the third ventricle with various doses of the alpha-MSH agonist MTII or artificial cerebrospinal fluid (aCSF): SAL + aCSF, SAL + MTII, NIC + aCSF, NIC + MTII.
Report a problemFND-1288812401
02AnimalAnimal study (in vivo)Efficacy outcome
In rats, MTII suppressed meal number during the dark phase.
In plain wordsIn rats, melanotan II reduced the number of night-time meals.
Peptide
Melanotan II
Outcome
DecreaseDark phase meal number after MTII
Study
ratn: not reported in source
Male Sprague Dawley rats with third ventricle cannulas, nicotine withdrawal
Comparator
Artificial cerebrospinal fluid (aCSF)
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
Dose not stated · third ventricle infusionAs given in this study (rat).
Source sentences
Summary
Meal number during the dark phase was suppressed by MTII
1 context sentence(design, population, supporting numbers)
Summary · context
On day 22, the rats were divided into 4 groups (n's = 7-8 each) and injected into the third ventricle with various doses of the alpha-MSH agonist MTII or artificial cerebrospinal fluid (aCSF): SAL + aCSF, SAL + MTII, NIC + aCSF, NIC + MTII.
Report a problemFND-1288812402
03AnimalAnimal study (in vivo)Efficacy outcome
In rats treated with saline or nicotine, MTII suppressed meal size.
In plain wordsIn rats, melanotan II made meals smaller, in both saline-treated and nicotine-treated rats.
Peptide
Melanotan II
Outcome
DecreaseMeal size after MTII
Study
ratn: not reported in source
Male Sprague Dawley rats with third ventricle cannulas, nicotine withdrawal
Comparator
Artificial cerebrospinal fluid (aCSF)
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
Dose not stated · third ventricle infusionAs given in this study (rat).
Source sentences
Summary
Infusion of MTII suppressed meal size in SAL and NIC treated rats
1 context sentence(design, population, supporting numbers)
Summary · context
On day 22, the rats were divided into 4 groups (n's = 7-8 each) and injected into the third ventricle with various doses of the alpha-MSH agonist MTII or artificial cerebrospinal fluid (aCSF): SAL + aCSF, SAL + MTII, NIC + aCSF, NIC + MTII.
Report a problemFND-1288812403
04AnimalAnimal study (in vivo)Efficacy outcome
In rats, all meal parameters had normalized by the day after the MTII infusion.
In plain wordsIn rats, eating patterns were back to normal the day after melanotan II infusion.
Peptide
Melanotan II
Outcome
No significant changeMeal parameters one day after infusion
Study
ratn: not reported in source
Male Sprague Dawley rats with third ventricle cannulas, nicotine withdrawal
Comparator
Artificial cerebrospinal fluid (aCSF)
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
Dose not stated · third ventricle infusionAs given in this study (rat).
Source sentences
Summary
All meal parameters normalized by the day after i.c.v. infusion.
1 context sentence(design, population, supporting numbers)
Summary · context
On day 22, the rats were divided into 4 groups (n's = 7-8 each) and injected into the third ventricle with various doses of the alpha-MSH agonist MTII or artificial cerebrospinal fluid (aCSF): SAL + aCSF, SAL + MTII, NIC + aCSF, NIC + MTII.
Report a problemFND-1288812404

Studies that did not test the peptide alone1

In this study, Melanotan II was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Melanotan II.

05AnimalNot a test of Melanotan II aloneAnimal study (in vivo)Efficacy outcome
In rats withdrawn from nicotine, the suppression of food intake, meal number and meal size by MTII was attenuated compared with saline-treated rats.
In plain wordsIn rats withdrawn from nicotine, melanotan II reduced eating less than in saline-treated rats.
Peptide
Melanotan II
Outcome
Not applicableAttenuation of MTII suppression of food intake and meals after nicotine withdrawal
Study
ratn: not reported in source
Male Sprague Dawley rats with third ventricle cannulas, nicotine withdrawal
Comparator
Saline plus MTII
Outcome group
Appetite and food intake · Metabolic and weight
Source sentences
Summary
but the NIC + MTII group ate (P < 0.05) more than the SAL + MTII group.
2 context sentences(design, population, supporting numbers)
Summary · context
These data indicate that NIC treatment differentially affects the neural controls of meal number and meal size and attenuates the suppression by MTII of meal number and meal size.
Summary · context
On day 22, the rats were divided into 4 groups (n's = 7-8 each) and injected into the third ventricle with various doses of the alpha-MSH agonist MTII or artificial cerebrospinal fluid (aCSF): SAL + aCSF, SAL + MTII, NIC + aCSF, NIC + MTII.
In this study, Melanotan II was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Melanotan II.
Report a problemFND-1288812405

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
10 Oct 2026, 09:43 UTC
Study results updated
Version 1
9 Oct 2026, 03:04 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.